TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21030496
Drug: Bevacizumab (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (15 mg/kg every 3 weeks) and fotemustine (100 mg/m² on days 1, 8, and 15, repeated after 4 weeks)
Study: 21030558
Drug: Ex vivo
Normalized name: Allogeneic ex vivo expanded umbilical cord blood cells
DrugBank: Carlecortemcel-L (DB17186)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ex vivo anti-CD3/anti-CD28 costimulated autologous T cells + pneumococcal conjugate vaccine + multipeptide tumor antigen vaccine
Study: 21030558
Drug: Pneumococcal conjugate
Normalized name: pneumococcal conjugate PCV 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pneumococcal conjugate vaccine only
Study: 21030579
Drug: Upper tertile
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Upper tertile of GFR (GFR>4.13 ml/min per 1.73 m2)
Study: 21030579
Drug: Anuric patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anuric patients (urinary output<100 ml/24 h)
Study: 21737309
Drug: 0.6 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg/kg alteplase
Study: 21034418
Drug: c-SN6j (chimeric
Approvals — FDA: no, EMA: no, PMDA: no
Description: c-SN6j (chimeric anti-ENG monoclonal antibody)
Study: 21035624
Drug: Armodafinil 100
Normalized name: armodafinil 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Armodafinil 100 mg PO
Study: 21035624
Drug: Armodafinil 250
Normalized name: armodafinil 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Armodafinil 250 mg PO
Study: 21035955
Drug: Vandetanib 100
Normalized name: vandetanib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vandetanib 100 mg daily with SRS
Study: 21041183
Drug: Bevacizumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (10 mg/kg i.v. every 2 weeks) plus Erlotinib (150 mg/d orally)
Study: 21041705
Drug: Alemtuzumab 10
Normalized name: alemtuzumab 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alemtuzumab 10 mg/d intravenously for 10 days
Study: 21042071
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin treatment for male pattern baldness
Study: 21042103
Drug: Indocyanine green
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Indocyanine green 4 mg per injection
Study: 21042103
Drug: Indocyanine green
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Indocyanine green 6 mg per injection
Study: 21042103
Drug: Indocyanine green
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Indocyanine green 2 mg per injection
Study: 21045179
Drug: Gamma imaging
Normalized name: Gamma Cyclodextrin
DrugBank: Gamma cyclodextrin (DB19173)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gamma imaging (740-mBq technetium 99m sestamibi injection)
Study: 21047224
Drug: Everolimus (3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus (3.0 mg/m² orally)
Study: 21047225
Drug: Brentuximab vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brentuximab vedotin (SGN-35) at a dose of 0.1 to 3.6 mg per kilogram of body weight every 3 weeks
Study: 21047927
Drug: High-calorie diet,
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-calorie diet, relative physical inactivity, and administration of prednisolone (37.5 mg/d) for 12 days
Study: 21051557
Drug: High-dose lenalidomide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose lenalidomide (50 mg daily for up to 2 cycles)
Study: 21051557
Drug: Low-dose lenalidomide
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose lenalidomide (10 mg daily after HD lenalidomide)
Study: 21051706
Drug: Intravitreal ranibizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal ranibizumab (0.05 mL) treatment
Study: 21055747
Drug: Quinagolide (25-75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinagolide (25-75 μg/d) administered for 18-20 weeks after L1
Study: 21055747
Drug: Quinagolide (25-75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinagolide (25-75 μg/d)
Study: 21059672
Drug: Anakinra (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anakinra (100 mg/day s.c.) and MTX
Study: 21060028
Drug: Cediranib at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cediranib at 12 mg/m(2)/d
Study: 21060028
Drug: Cediranib at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cediranib at 8 mg/m(2)/d
Study: 21060028
Drug: Cediranib at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cediranib at 17 mg/m(2)/d
Study: 21062137
Drug: Aliskiren/valsartan/HCT (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren/valsartan/HCT (12.5 or 25 mg)
Study: 21062428
Drug: Standard photon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard photon treatment
Study: 21069335
Drug: Pemetrexed (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed (500 mg/m(2)) and Docetaxel (75 mg/m(2))
Study: 21069335
Drug: Pemetrexed and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed and Docetaxel (escalating doses)
Study: 21070142
Drug: Artesunate 6
Normalized name: artesunate 60 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artesunate 6 mg/kg/day for 7 days
Study: 21070142
Drug: Artesunate 4
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Artesunate 4 mg/kg/day for 7 days
Study: 21070142
Drug: Artesunate 2
Normalized name: Artesunate 25 mg and mefloquine (as mefloquine hydrochloride) 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artesunate 2 mg/kg/day for 7 days
Study: 21071497
Drug: Deferasirox therapy
Normalized name: Deferasirox
DrugBank: Deferasirox (DB01609)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Deferasirox therapy (mean dose 36.1 ± 7.7 mg/kg/d during the second year)
Study: 21073392
Drug: Lansoprazole (median
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole (median dose 90 mg/day)
Study: 21075272
Drug: Morphine sulfate
Normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine sulfate and naltrexone hydrochloride extended release capsules (MS-sNT)
Study: 21078419
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy regimens with anthracyclines or anthracycline/taxane combination
Study: 21078419
Drug: EORTC QLQ-C30
Approvals — FDA: no, EMA: no, PMDA: no
Description: EORTC QLQ-C30 (European Organization for Research and Treatment Quality of Life Questionnaire)
Study: 21079154
Drug: BEACOPP chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BEACOPP chemotherapy (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone)
Study: 21079154
Drug: Consolidation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consolidation therapy for rapid responders (females: 4 cycles of COPP/ABV without IFRT; males: 2 cycles of ABVD with IFRT)
Study: 21079154
Drug: BEACOPP chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BEACOPP chemotherapy with IFRT for slow responders
Study: 21079158
Drug: Control (age-matched,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (age-matched, no oncological treatment)
Study: 21083543
Drug: Adalimumab retreatment
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adalimumab retreatment (80 mg at week 0 and 40 mg eow starting at week 1)
Study: 21085552
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) consisting of 6 weekly sessions and 3 telephone booster calls.
Study: 21086246
Drug: Lanreotide Autogel®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanreotide Autogel® 120 mg at 56-day interval
Study: 21086246
Drug: Lanreotide Autogel®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanreotide Autogel® 120 mg at 42-day interval
Study: 21086246
Drug: Lanreotide Autogel®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanreotide Autogel® 120 mg at 28-day interval
Study: 21086246
Drug: Lanreotide Autogel®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanreotide Autogel® 120 mg
Study: 21087953
Drug: Ciliary neurotrophic
Normalized name: CILIARY NEUROTROPHIC FACTOR
DrugBank: Ciliary neurotrophic factor (DB05344)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciliary neurotrophic factor (CNTF) treatment delivered by an encapsulated cell technology implant in one eye
Study: 21087958
Drug: Intravitreal bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal bevacizumab (1.25 mg) or ranibizumab (0.5 mg)
Study: 21093024
Drug: AMG 317
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 317 (IL-4 receptor α antagonist)
Study: 21093448
Drug: ANRS HIV-LIPO-5
Normalized name: HIV
Approvals — FDA: no, EMA: no, PMDA: no
Description: ANRS HIV-LIPO-5 Vaccine (dendritic cell vaccine loaded with HIV-1-antigen lipopeptides)
Study: 21093448
Drug: ANRS HIV-LIPO-5
Normalized name: HIV
Approvals — FDA: no, EMA: no, PMDA: no
Description: ANRS HIV-LIPO-5 Vaccine
Study: 21094089
Drug: Navitoclax (14/21
Approvals — FDA: no, EMA: no, PMDA: no
Description: Navitoclax (14/21 dosing schedule) at doses of 10, 20, 40, 80, 110, 160, 225, 315, or 440 mg/day
Study: 21094089
Drug: Navitoclax (21/21
Approvals — FDA: no, EMA: no, PMDA: no
Description: Navitoclax (21/21 dosing schedule) at doses of 200, 275, 325, or 425 mg/day
Study: 21094089
Drug: Navitoclax (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Navitoclax (150 mg/day lead-in dose followed by 325 mg on continuous 21/21 schedule)
Study: 21098436
Drug: Bioresorbable everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bioresorbable everolimus drug-eluting vascular scaffold
Study: 21107682
Drug: Everolimus 5
Normalized name: everolimus 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 5 mg/day plus vinorelbine and trastuzumab
Study: 21107682
Drug: Everolimus 30
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus 30 mg/week plus vinorelbine and trastuzumab
Study: 21107682
Drug: Everolimus 20
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus 20 mg/week plus vinorelbine and trastuzumab
Study: 21108818
Drug: Prepandemic (H5N1)
Normalized name: influenza, H5N1-1203
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prepandemic (H5N1) influenza vaccine adjuvanted with AS03A (3.75 μg haemagglutinin)
Study: 21108818
Drug: Prepandemic (H5N1)
Normalized name: influenza, H5N1-1203
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prepandemic (H5N1) influenza vaccine adjuvanted with AS03A
Study: 21109011
Drug: Tandem high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tandem high-dose therapy (HDT) with autologous peripheral blood stem cell (PBSC) support; Induction with anthracyclin-containing regimen followed by tandem HDT conditioned by high-dose mitoxantrone plus cytarabine for the first HDT and total-body irradiation (TBI), carmustine, etoposide, and cyclophosphamide for the second HDT
Study: 21109011
Drug: Tandem high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tandem high-dose therapy (HDT) with autologous peripheral blood stem cell (PBSC) support
Study: 21109229
Drug: Phototherapeutic keratectomy
Normalized name: Other chemotherapeutics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phototherapeutic keratectomy (PTK) with low-dose mitomycin C (MMC) 0.002% for 1 minute
Study: 21111785
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose (5.0mg, n=12)
Study: 21111785
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose (1.0mg, n=10)
Study: 21115606
Drug: Daily and/or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily and/or weekly symptom variability
Study: 21115606
Drug: Impact on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Impact on daily activities
Study: 21115606
Drug: Adjustment of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjustment of treatment
Study: 21117946
Drug: Candesartan 32
Normalized name: candesartan 32 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan 32 mg + Hydrochlorothiazide 25 mg (Phase 1)
Study: 21117946
Drug: Aliskiren 300
Normalized name: aliskiren 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren 300 mg + Hydrochlorothiazide 25 mg (Phase 2)
Study: 21117946
Drug: Aliskiren 300
Normalized name: aliskiren 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren 300 mg + Hydrochlorothiazide 25 mg + Amlodipine 5 mg (optional extension)
Study: 21118739
Drug: New disposable
Approvals — FDA: no, EMA: no, PMDA: no
Description: New disposable rhGH injection pen
Study: 21123449
Drug: Continuous Positive
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous Positive Airway Pressure (CPAP) treatment for obstructive sleep apnea (OSA) for 8 weeks
Study: 21123825
Drug: L-asparaginase-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-asparaginase-based treatment
Study: 21131369
Drug: Brivanib alaninate
Normalized name: Brivanib alaninate
DrugBank: Brivanib alaninate (DB11865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brivanib alaninate at doses of 800 mg/day (continuous)
Study: 21131369
Drug: Brivanib alaninate
Normalized name: Brivanib alaninate
DrugBank: Brivanib alaninate (DB11865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brivanib alaninate at doses of 400 mg b.i.d.
Study: 21131369
Drug: Brivanib alaninate
Normalized name: Brivanib alaninate
DrugBank: Brivanib alaninate (DB11865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brivanib alaninate at doses of 800 mg/day (intermittent)
Study: 21131369
Drug: Brivanib alaninate
Normalized name: Brivanib alaninate
DrugBank: Brivanib alaninate (DB11865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brivanib alaninate at doses of 180-800 mg
Study: 21131369
Drug: Brivanib alaninate
Normalized name: Brivanib alaninate
DrugBank: Brivanib alaninate (DB11865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brivanib alaninate at doses ≤1000 mg/day
Study: 21131369
Drug: Brivanib alaninate
Normalized name: Brivanib alaninate
DrugBank: Brivanib alaninate (DB11865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brivanib alaninate at maximum tolerated dose (MTD) of 800 mg/day
Study: 21131552
Drug: ENMD-2076 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ENMD-2076 at 200 mg/m(2)
Study: 21131552
Drug: ENMD-2076 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ENMD-2076 at 160 mg/m(2) (MTD)
Study: 21131552
Drug: ENMD-2076 (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: ENMD-2076 (various doses: 60, 80, 120, 160, 200 mg/m(2))
Study: 21134243
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg sotrastaurin once between days 1-3 and once between days 5-8 post-transplant
Study: 21134985
Drug: PR1 and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: PR1 and WT1 peptides in Montanide-adjuvant with GM-CSF, administered every two weeks for a total of 6 injections
Study: 21134985
Drug: Booster injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster injection three months after the 6th vaccine dose
Study: 21135251
Drug: Mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin C treatment
Study: 21138605
Drug: Wheat bran
Normalized name: Wheat bran
DrugBank: Wheat bran (DB10685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wheat bran (9 g)
Study: 21138939
Drug: sFlt-1 >84
Approvals — FDA: no, EMA: no, PMDA: no
Description: sFlt-1 >84 ng/L
Study: 21138939
Drug: PlGF >20
Approvals — FDA: no, EMA: no, PMDA: no
Description: PlGF >20 ng/L
Study: 21138939
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of troponin T and sFlt-1
Study: 21139575
Drug: Low-dose peginterferon
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose peginterferon α2a
Study: 21140148
Drug: Imatinib (dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib (dosing modified to achieve target plasma levels)
Study: 21142268
Drug: Exenatide ER
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide ER 0.8 mg
Study: 21142268
Drug: Exenatide ER
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide ER 2 mg
Study: 21143432
Drug: Extended release
Normalized name: Tylenol Extended Release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended release methylphenidate (OROS MPH) at a mean dose of 54 mg/day (0.90 mg/kg/day)
Study: 21145590
Drug: Daunorubicin combined
Normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daunorubicin combined with imatinib mesylate (600 mg/d) and cytarabine (200 mg/d for 7 days)
Study: 21145590
Drug: Daunorubicin at
Normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daunorubicin at 30-45 mg/m(2)/d
Study: 21145590
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of IM with a standard '3+7' regimen
Study: 21145720
Drug: 24 μg
Normalized name: penicillin G 24 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 μg formoterol
Study: 21145855
Drug: PEG-IFN therapy
Normalized name: PEG IFN-beta-1a
DrugBank: Peginterferon beta-1a (DB09122)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PEG-IFN therapy (0-4 weeks)
Study: 21145855
Drug: PEG-IFN therapy
Normalized name: PEG IFN-beta-1a
DrugBank: Peginterferon beta-1a (DB09122)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PEG-IFN therapy (5-19 weeks)
Study: 21145855
Drug: PEG-IFN therapy
Normalized name: PEG IFN-beta-1a
DrugBank: Peginterferon beta-1a (DB09122)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PEG-IFN therapy (20-23 weeks)
Study: 21145855
Drug: PEG-IFN therapy
Normalized name: PEG IFN-beta-1a
DrugBank: Peginterferon beta-1a (DB09122)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PEG-IFN therapy (24 weeks)
Study: 21145855
Drug: Missed doses
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Missed doses during therapy
Study: 21148334
Drug: Surgical resection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical resection followed by chemotherapy
Study: 21148530
Drug: Adjuvanted pandemic
Normalized name: pangamate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvanted pandemic H1N1 influenza vaccine (A/California/7/2009)
Study: 21148532
Drug: Monovalent 2009
Normalized name: influenza a (H1N1) virus vaccine monovalent 2009
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monovalent 2009 influenza A (H1N1) vaccine (strain A/California/7/2009H1N1)
Study: 21148613
Drug: Sunitinib 50
Normalized name: sunitinib 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib 50 mg orally days 1-28, every 42 days (1 cycle)
Study: 21149673
Drug: Lenalidomide 15
Normalized name: lenalidomide 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide 15 mg/m2/dose
Study: 21149673
Drug: Lenalidomide 40
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide 40 mg/m2/dose
Study: 21149673
Drug: Lenalidomide 55
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide 55 mg/m2/dose
Study: 21149673
Drug: Lenalidomide 70
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide 70 mg/m2/dose
Study: 21155613
Drug: rhPTH(1-84) 100
Normalized name: rhPTH
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rhPTH(1-84) 100 μg, administered once daily as a subcutaneous injection for 12 months
Study: 21156020
Drug: AMG 102
Normalized name: AMG 102
DrugBank: Rilotumumab (DB11972)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 102 at 10 mg/kg
Study: 21156020
Drug: AMG 102
Normalized name: AMG 102
DrugBank: Rilotumumab (DB11972)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 102 at 20 mg/kg
Study: 21156020
Drug: AMG 102
Normalized name: AMG 102
DrugBank: Rilotumumab (DB11972)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 102 (both doses)
Study: 21163497
Drug: Single patch
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single patch repair
Study: 21163497
Drug: Double patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double patch repair
Study: 21163497
Drug: Single atrial
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single atrial septal defect patch with primary ventricular septal defect closure
Study: 21163927
Drug: G-CSF (lenograstim,
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF (lenograstim, 263 μg)
Study: 21167116
Drug: Trivalent seasonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent seasonal influenza vaccine (15μg of hemagglutinin of each virus strain)
Study: 21169856
Drug: Febuxostat (40,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Febuxostat (40, 80, or 120 mg daily for up to 5 years)
Study: 21170669
Drug: Saracatinib 175
Normalized name: Saracatinib
DrugBank: Saracatinib (DB11805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saracatinib 175 mg PO daily in combination with gemcitabine (1000 mg/m(2))
Study: 21172791
Drug: 400/100 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400/100 mg lopinavir/ritonavir twice daily
Study: 21172791
Drug: 200/150 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200/150 mg lopinavir/ritonavir twice daily
Study: 21172791
Drug: 200/50 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200/50 mg lopinavir/ritonavir twice daily
Study: 21173095
Drug: Subcutaneous veltuzumab
Normalized name: elotuzumab
DrugBank: Elotuzumab (DB06317)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous veltuzumab 80 mg
Study: 21173095
Drug: Subcutaneous veltuzumab
Normalized name: elotuzumab
DrugBank: Elotuzumab (DB06317)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous veltuzumab 160 mg